Topical Ruxolitinib Effective for Vitiligo in Adolescents

Ruxolitinib cream is under review at the US Food and Drug Administration for treating vitiligo in patients ages 12 years and older; the agency is expected to make a decision by July 18.
Medscape Medical News

source https://www.medscape.com/viewarticle/976781?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?